| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8001595d1f477dc05f503279db8e1e2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_91f9d00bbbff9c284aa2aeb183260ccc |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2021-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61a4803917ec03777f94ddc91de77aeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd6c5d7e7b0a5211b90deb748780034a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_816ea30e98a7fe4112667c771a5959e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4e157a9e5f0d3a8285e1a184802e4d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8281ee779ab37dd62253517e9f44261 |
| publicationDate |
2022-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114177168-A |
| titleOfInvention |
Application of simvastatin in the preparation of drugs for preventing or treating liver cancer |
| abstract |
The invention belongs to the field of medicine, and in particular relates to the application of simvastatin in the preparation of a medicine for preventing or treating liver cancer. The results of pharmacological experiments showed that simvastatin could inhibit the proliferation, migration and invasion of liver cancer cells HepG2, and promote the apoptosis of liver cancer cells. In addition, the medicament further comprises a second active ingredient which is an immune checkpoint inhibitor. The results of pharmacological experiments showed that the drug containing the second active ingredient significantly inhibited the growth of human hepatoma Hep3B transplanted tumor in nude mice, and the effect was significantly better than that of the same dose of simvastatin and immune checkpoint inhibitor alone. It has a significant synergistic effect and has a good clinical application prospect. |
| priorityDate |
2021-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |